DCM
NVO

DGS Capital Management’s Novo Nordisk NVO Stock Holding History

DGS Capital Management’s Portfolio NVO Stock Details NVO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-100
Closed -$5.09K – 683
2025
Q4 		$5.09K Buy
+100
New +$5.11K ﹤0.01% 542

Other funds holding NVO

Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
Loomis, Sayles & Company
Loomis, Sayles & Company Boston, Massachusetts $74.3B AUM 24.01% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
DAM
Diamant Asset Management Ridgefield, Connecticut $137B AUM 18.02% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
F
Folketrygdfondet Oslo Norway, Norway $5.64B AUM 47.16% 1-Year Est. Return

DGS Capital Management's NVO Position: Q1 2026 in Review

DGS Capital Management increased its Novo Nordisk (NVO) stake by 2.1% in Q1 2026, buying an estimated $31.6K and bringing the position to 31,948 shares worth $1.17M. The position accounts for 0.19% of the portfolio, ranked #99.

DGS Capital Management first reported a position in NVO in Q4 2021 and has held it in 18 quarters since. The position peaked at $6.05M in Q2 2024. 1,272 funds tracked by Wall St. Rank hold NVO as of Q1 2026.

  • DGS Capital Management held 31,948 shares of Novo Nordisk worth $1.17M as of Q1 2026.
  • DGS Capital Management bought 667 Novo Nordisk shares in Q1 2026, an estimated $31.6K.
  • Novo Nordisk made up 0.19% of DGS Capital Management's portfolio in Q1 2026, its #99 holding.
  • DGS Capital Management first reported a position in Novo Nordisk in Q4 2021 and has held it in 18 quarters since.
  • DGS Capital Management's Novo Nordisk position peaked at $6.05M in Q2 2024.
  • 1,272 funds tracked by Wall St. Rank held Novo Nordisk as of Q1 2026.

Based on DGS Capital Management's 13F filing for Q1 2026, filed 28 Apr 2026.